Skip to main content

Table 2 Baseline imaging characteristics

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

MRI
 Synovitis (%)66.7%
  PSAMRIS synovitis (median, IQR)1 (0, 2)
  PSAMRIS synovitis (mean ± SD)2.17 ± 4.6
 Osteitis (%)27.8%
  PSAMRIS osteitis (median, IQR)0 (0, 0)
  PSAMRIS osteitis (mean ± SD)0.44 ± 1.89
 Erosion (%)72.2%
  PSAMRIS erosion (median, IQR)1 (0, 4)
  PSAMRIS erosion (mean ± SD)2.56 ± 3.7
 Proliferation (%)33.3%
  PSAMRIS proliferation (median, IQR)0 (0, 1)
  PSAMRIS proliferation (mean ± SD)0.44 ± 0.71
 Periarticular (%)16.7%
  PSAMRIS periarticular (median, IQR)0 (0, 0)
  PSAMRIS periarticular (mean ± SD)0.28 ± 0.67
 Tenosynovitis (%)55.6%
  PSAMRIS tenosynovitis (median, IQR)0 (0, 1)
  PSAMRIS tenosynovitis (mean ± SD)0.61 ± 1.15
 Total PSAMRIS (median, IQR)4 (0.75, 7.25)
 Total PSAMRIS (mean ± SD)6.5 ± 8.85
HR-pQCT
 Erosions (%)58.8%
  Erosion no. (median, IQR)1 (0, 1.75)
 Enthesiophytes (%)41.2%
  Grade 123.5%
  Grade 217.6%
  Grade 30%
  1. Data are based on 18 psoriasis patients who completed the study
  2. PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system, MRI magnetic resonance imaging, HR-pQCT high-resolution peripheral quantitative computed tomography, IQR interquartile range, SD standard deviation